Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy

Arjun Sahgal, Joe H. Chang, Lijun Ma, Lawrence B. Marks, Michael T. Milano, Paul Medin, Andrzej Niemierko, Scott G. Soltys, Wolfgang A. Tomé, C. Shun Wong, Ellen Yorke, Jimm Grimm, Andrew Jackson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Spinal cord tolerance data for stereotactic body radiation therapy (SBRT) were extracted from published reports, reviewed, and modelled. For de novo SBRT delivered in 1 to 5 fractions, the following spinal cord point maximum doses (Dmax) are estimated to be associated with a 1% to 5% risk of radiation myelopathy (RM): 12.4 to 14.0 Gy in 1 fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23.0 Gy in 4 fractions, and 25.3 Gy in 5 fractions. For reirradiation SBRT delivered in 1 to 5 fractions, reported factors associated with a lower risk of RM include cumulative thecal sac equivalent dose in 2 Gy fractions with an alpha/beta of 2 (EQD22) Dmax ≤70 Gy; SBRT thecal sac EQD22 Dmax ≤25 Gy, thecal sac SBRT EQD22 Dmax to cumulative EQD22 Dmax ratio ≤0.5, and a minimum time interval to reirradiation of ≥5 months. Larger studies containing complete institutional cohorts with dosimetric data of patients treated with spine SBRT, with and without RM, are required to refine RM risk estimates.

Original languageEnglish (US)
JournalInternational Journal of Radiation Oncology Biology Physics
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

spinal cord
radiation therapy
Spinal Cord
Radiotherapy
Spinal Cord Diseases
dosage
Radiation
radiation
spine
Spine
intervals
estimates

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Sahgal, A., Chang, J. H., Ma, L., Marks, L. B., Milano, M. T., Medin, P., ... Jackson, A. (Accepted/In press). Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics. https://doi.org/10.1016/j.ijrobp.2019.09.038

Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy. / Sahgal, Arjun; Chang, Joe H.; Ma, Lijun; Marks, Lawrence B.; Milano, Michael T.; Medin, Paul; Niemierko, Andrzej; Soltys, Scott G.; Tomé, Wolfgang A.; Wong, C. Shun; Yorke, Ellen; Grimm, Jimm; Jackson, Andrew.

In: International Journal of Radiation Oncology Biology Physics, 01.01.2019.

Research output: Contribution to journalArticle

Sahgal, A, Chang, JH, Ma, L, Marks, LB, Milano, MT, Medin, P, Niemierko, A, Soltys, SG, Tomé, WA, Wong, CS, Yorke, E, Grimm, J & Jackson, A 2019, 'Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy', International Journal of Radiation Oncology Biology Physics. https://doi.org/10.1016/j.ijrobp.2019.09.038
Sahgal, Arjun ; Chang, Joe H. ; Ma, Lijun ; Marks, Lawrence B. ; Milano, Michael T. ; Medin, Paul ; Niemierko, Andrzej ; Soltys, Scott G. ; Tomé, Wolfgang A. ; Wong, C. Shun ; Yorke, Ellen ; Grimm, Jimm ; Jackson, Andrew. / Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy. In: International Journal of Radiation Oncology Biology Physics. 2019.
@article{9fe7e99249e94531ba900225b3f78267,
title = "Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy",
abstract = "Spinal cord tolerance data for stereotactic body radiation therapy (SBRT) were extracted from published reports, reviewed, and modelled. For de novo SBRT delivered in 1 to 5 fractions, the following spinal cord point maximum doses (Dmax) are estimated to be associated with a 1{\%} to 5{\%} risk of radiation myelopathy (RM): 12.4 to 14.0 Gy in 1 fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23.0 Gy in 4 fractions, and 25.3 Gy in 5 fractions. For reirradiation SBRT delivered in 1 to 5 fractions, reported factors associated with a lower risk of RM include cumulative thecal sac equivalent dose in 2 Gy fractions with an alpha/beta of 2 (EQD22) Dmax ≤70 Gy; SBRT thecal sac EQD22 Dmax ≤25 Gy, thecal sac SBRT EQD22 Dmax to cumulative EQD22 Dmax ratio ≤0.5, and a minimum time interval to reirradiation of ≥5 months. Larger studies containing complete institutional cohorts with dosimetric data of patients treated with spine SBRT, with and without RM, are required to refine RM risk estimates.",
author = "Arjun Sahgal and Chang, {Joe H.} and Lijun Ma and Marks, {Lawrence B.} and Milano, {Michael T.} and Paul Medin and Andrzej Niemierko and Soltys, {Scott G.} and Tom{\'e}, {Wolfgang A.} and Wong, {C. Shun} and Ellen Yorke and Jimm Grimm and Andrew Jackson",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2019.09.038",
language = "English (US)",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy

AU - Sahgal, Arjun

AU - Chang, Joe H.

AU - Ma, Lijun

AU - Marks, Lawrence B.

AU - Milano, Michael T.

AU - Medin, Paul

AU - Niemierko, Andrzej

AU - Soltys, Scott G.

AU - Tomé, Wolfgang A.

AU - Wong, C. Shun

AU - Yorke, Ellen

AU - Grimm, Jimm

AU - Jackson, Andrew

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Spinal cord tolerance data for stereotactic body radiation therapy (SBRT) were extracted from published reports, reviewed, and modelled. For de novo SBRT delivered in 1 to 5 fractions, the following spinal cord point maximum doses (Dmax) are estimated to be associated with a 1% to 5% risk of radiation myelopathy (RM): 12.4 to 14.0 Gy in 1 fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23.0 Gy in 4 fractions, and 25.3 Gy in 5 fractions. For reirradiation SBRT delivered in 1 to 5 fractions, reported factors associated with a lower risk of RM include cumulative thecal sac equivalent dose in 2 Gy fractions with an alpha/beta of 2 (EQD22) Dmax ≤70 Gy; SBRT thecal sac EQD22 Dmax ≤25 Gy, thecal sac SBRT EQD22 Dmax to cumulative EQD22 Dmax ratio ≤0.5, and a minimum time interval to reirradiation of ≥5 months. Larger studies containing complete institutional cohorts with dosimetric data of patients treated with spine SBRT, with and without RM, are required to refine RM risk estimates.

AB - Spinal cord tolerance data for stereotactic body radiation therapy (SBRT) were extracted from published reports, reviewed, and modelled. For de novo SBRT delivered in 1 to 5 fractions, the following spinal cord point maximum doses (Dmax) are estimated to be associated with a 1% to 5% risk of radiation myelopathy (RM): 12.4 to 14.0 Gy in 1 fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23.0 Gy in 4 fractions, and 25.3 Gy in 5 fractions. For reirradiation SBRT delivered in 1 to 5 fractions, reported factors associated with a lower risk of RM include cumulative thecal sac equivalent dose in 2 Gy fractions with an alpha/beta of 2 (EQD22) Dmax ≤70 Gy; SBRT thecal sac EQD22 Dmax ≤25 Gy, thecal sac SBRT EQD22 Dmax to cumulative EQD22 Dmax ratio ≤0.5, and a minimum time interval to reirradiation of ≥5 months. Larger studies containing complete institutional cohorts with dosimetric data of patients treated with spine SBRT, with and without RM, are required to refine RM risk estimates.

UR - http://www.scopus.com/inward/record.url?scp=85074778645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074778645&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2019.09.038

DO - 10.1016/j.ijrobp.2019.09.038

M3 - Article

C2 - 31606528

AN - SCOPUS:85074778645

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

ER -